Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemDiv, a contract research organization or CRO, has announced that its ChemRar High Tech Center has acquired Prudentas, a CRO conducting Phase I to Phase IV studies in Eastern Europe. Prudentas will continue to operate separately under the business name Prudentas LLC, a ChemDiv Group company.
Subscribe to our email newsletter
ChemDiv sees great potential in this acquisition by adding value to ChemDiv’s Discovery outSource services offered to pharmaceutical and biotech companies worldwide.
Nikolay Savchuk, president and CEO of ChemDiv, said: “This acquisition is synergistic to the continued development of our Chemical Diversity Research Institute subsidiary, and our other discovery services holdings such as Drugs Technology, which provides good laboratory practice/good manufacturing practice formulation and CMC services.
“We believe Prudentas will help us bring unique levels of clinical development productivity to pharma and biotech partners through risk mitigation, cost- and time savings. This acquisition further strengthens and expands our global presence specifically in the Eastern European and Eurasian markets and responds to growing customer demand for comprehensive R&D outsourcing.”